Citi opened a “high conviction 90-day Upside Catalyst Watch” on shares of Arcturus Therapeutics (ARCT). The firm keeps a Buy rating on the name with a $44 price target The company’s decision to rationalize spend and discontinue early-stage mRNA vaccine efforts with low return on investment visibility and “lower Street visibility” was smart, the analyst tells investors in a research note. Citi says Arcturus has two near-term pipeline catalysts mid-2025, and is trading marginally above cash.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARCT:
- Strategic Shift to mRNA Therapeutics Positions Arcturus for Significant Upside
- Arcturus Therapeutics: Promising Vaccine Rollout and Cystic Fibrosis Treatment Drive Buy Rating
- Arcturus Therapeutics Reports Q1 2025 Financial Update
- Arcturus Therapeutics reports Q1 EPS (52c), consensus ($1.10)
- ARCT Earnings Report this Week: Is It a Buy, Ahead of Earnings?